The Immunobiology of viral arthritides

Andreas Suhrbier, Suresh Mahalingam

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A large range of human viruses are associated with the development of arthritis or arthralgia. Although there are many parallels with autoimmune arthritides, there is little evidence that viral arthritides lead to autoimmune disease. In humans viral arthritides usually last from weeks to months, can be debilitating, and are usually treated with non-steroidal anti-inflammatory drugs, but with variable success. Viral arthritides likely arise from immunopathological inflammatory responses directed at viruses and/or their products residing and/or replicating within joint tissues. Macrophages recruited by monocyte chemoattractant protein-1 (MCP-1/CCL2) and activated by interferon, and proinflammatory mediators like tumour necrosis factor α, interferon γ, interleukin-6 and interleukin-1β appear to be common elements in this group of diseases. The challenge for new treatments is to target excessive inflammation without compromising anti-viral immunity. Recent evidence from mouse models suggests targeting MCP-1 or complement may emerge as viable new treatment options for viral arthritides.
Original languageEnglish
Pages (from-to)301-308
Number of pages8
JournalPharmacology Therapeutics
Volume124
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Infectious Arthritis
Interferons
Arthritis
Complement C1
Viruses
Chemokine CCL2
Arthralgia
Interleukin-1
Autoimmune Diseases
Immunity
Interleukin-6
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Joints
Macrophages
Inflammation
Therapeutics
Pharmaceutical Preparations

Cite this

Suhrbier, Andreas ; Mahalingam, Suresh. / The Immunobiology of viral arthritides. In: Pharmacology Therapeutics. 2009 ; Vol. 124, No. 3. pp. 301-308.
@article{f1717e662ea441be88da258832e11748,
title = "The Immunobiology of viral arthritides",
abstract = "A large range of human viruses are associated with the development of arthritis or arthralgia. Although there are many parallels with autoimmune arthritides, there is little evidence that viral arthritides lead to autoimmune disease. In humans viral arthritides usually last from weeks to months, can be debilitating, and are usually treated with non-steroidal anti-inflammatory drugs, but with variable success. Viral arthritides likely arise from immunopathological inflammatory responses directed at viruses and/or their products residing and/or replicating within joint tissues. Macrophages recruited by monocyte chemoattractant protein-1 (MCP-1/CCL2) and activated by interferon, and proinflammatory mediators like tumour necrosis factor α, interferon γ, interleukin-6 and interleukin-1β appear to be common elements in this group of diseases. The challenge for new treatments is to target excessive inflammation without compromising anti-viral immunity. Recent evidence from mouse models suggests targeting MCP-1 or complement may emerge as viable new treatment options for viral arthritides.",
author = "Andreas Suhrbier and Suresh Mahalingam",
year = "2009",
doi = "10.1016/j.pharmthera.2009.09.005",
language = "English",
volume = "124",
pages = "301--308",
journal = "Pharmacology Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

The Immunobiology of viral arthritides. / Suhrbier, Andreas; Mahalingam, Suresh.

In: Pharmacology Therapeutics, Vol. 124, No. 3, 2009, p. 301-308.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Immunobiology of viral arthritides

AU - Suhrbier, Andreas

AU - Mahalingam, Suresh

PY - 2009

Y1 - 2009

N2 - A large range of human viruses are associated with the development of arthritis or arthralgia. Although there are many parallels with autoimmune arthritides, there is little evidence that viral arthritides lead to autoimmune disease. In humans viral arthritides usually last from weeks to months, can be debilitating, and are usually treated with non-steroidal anti-inflammatory drugs, but with variable success. Viral arthritides likely arise from immunopathological inflammatory responses directed at viruses and/or their products residing and/or replicating within joint tissues. Macrophages recruited by monocyte chemoattractant protein-1 (MCP-1/CCL2) and activated by interferon, and proinflammatory mediators like tumour necrosis factor α, interferon γ, interleukin-6 and interleukin-1β appear to be common elements in this group of diseases. The challenge for new treatments is to target excessive inflammation without compromising anti-viral immunity. Recent evidence from mouse models suggests targeting MCP-1 or complement may emerge as viable new treatment options for viral arthritides.

AB - A large range of human viruses are associated with the development of arthritis or arthralgia. Although there are many parallels with autoimmune arthritides, there is little evidence that viral arthritides lead to autoimmune disease. In humans viral arthritides usually last from weeks to months, can be debilitating, and are usually treated with non-steroidal anti-inflammatory drugs, but with variable success. Viral arthritides likely arise from immunopathological inflammatory responses directed at viruses and/or their products residing and/or replicating within joint tissues. Macrophages recruited by monocyte chemoattractant protein-1 (MCP-1/CCL2) and activated by interferon, and proinflammatory mediators like tumour necrosis factor α, interferon γ, interleukin-6 and interleukin-1β appear to be common elements in this group of diseases. The challenge for new treatments is to target excessive inflammation without compromising anti-viral immunity. Recent evidence from mouse models suggests targeting MCP-1 or complement may emerge as viable new treatment options for viral arthritides.

U2 - 10.1016/j.pharmthera.2009.09.005

DO - 10.1016/j.pharmthera.2009.09.005

M3 - Article

VL - 124

SP - 301

EP - 308

JO - Pharmacology Therapeutics

JF - Pharmacology Therapeutics

SN - 0163-7258

IS - 3

ER -